Symptom provocation studies in psychiatric disorders: Scientific value, risks, and future

被引:26
作者
D'Souza, DC
Berman, RM
Krystal, JH
Charney, DS
机构
[1] VA Connecticut Healthcare Syst, Psychiat Serv, Schizophrenia Biol Res Ctr, West Haven, CT 06516 USA
[2] Connecticut Mental Hlth Ctr, Abraham Ribicoff Res Ctr, New Haven, CT USA
[3] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA
关键词
symptom-provocation; benefits; risks; safeguards; bioethics; psychiatry institutional review board;
D O I
10.1016/S0006-3223(99)00209-7
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Several lines of investigation have contributed to the increasing recognition of the biological basis of psychiatric disorders. Symptom provocation studies have made important contributions toward this. With the emergence of novel methodologies, the role of symptom provocation studies has come under increasing scrutiny and debate. The scientific contributions and risks of symptom provocation studies are discussed using the psychostimulant paradigm in schizophrenia research as the prototypical study. The application of studies in other areas of medicine that carry risks similar to those associated with symptom provocation studies, are also reviewed. The authors draw on the parallel of cardiac stress testing to highlight risks:benefits issues. Finally, the authors discuss the future of symptom provocation studies and emphasize that these studies will need to meet the highest scientific tandards, ethical standards and safeguards. (C) 1999 Society of Biological Psychiatry.
引用
收藏
页码:1060 / 1080
页数:21
相关论文
共 154 条
[1]  
ABELSON M, 1998, OCULAR PHARM THER, V4, P533
[2]  
Abi-Dargham A, 1998, AM J PSYCHIAT, V155, P761
[3]  
ANAND A, 1997, 36 ANN M AM COLL NEU, P251
[4]   RECEPTOR ACTIVITY AND TURNOVER OF DOPAMINE AND NORADRENALINE AFTER NEUROLEPTICS [J].
ANDEN, NE ;
BUTCHER, SG ;
CORRODI, H ;
FUXE, K ;
UNGERSTEDT, U .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1970, 11 (03) :303-+
[5]   SYMPTOMS, SIGNS, AND DIAGNOSIS OF SCHIZOPHRENIA [J].
ANDREASEN, NC .
LANCET, 1995, 346 (8973) :477-481
[6]   PARTIAL IMPROVEMENT IN NEGATIVE SCHIZOPHRENIC SYMPTOMS AFTER AMPHETAMINE [J].
ANGRIST, B ;
PESELOW, E ;
RUBINSTEIN, M ;
CORWIN, J ;
ROTROSEN, J .
PSYCHOPHARMACOLOGY, 1982, 78 (02) :128-130
[7]   DIFFERENTIAL-EFFECTS OF AMPHETAMINE AND NEUROLEPTICS ON NEGATIVE VS POSITIVE SYMPTOMS IN SCHIZOPHRENIA [J].
ANGRIST, B ;
ROTROSEN, J ;
GERSHON, S .
PSYCHOPHARMACOLOGY, 1980, 72 (01) :17-19
[8]   AMPHETAMINE RESPONSE AND RELAPSE RISK AFTER DEPOT NEUROLEPTIC DISCONTINUATION [J].
ANGRIST, B ;
PESELOW, E ;
RUBINSTEIN, M ;
WOLKIN, A ;
ROTROSEN, J .
PSYCHOPHARMACOLOGY, 1985, 85 (03) :277-283
[9]  
ANGRIST B, 1974, AM J PSYCHIAT, V131, P817
[10]  
ANGRIST B, 1981, RECENT ADV NEUROPSYC, V31, P49